Tectonic Therapeutic (TECX) EBIT (2017 - 2026)

Tectonic Therapeutic (TECX) has reported EBIT for 10 consecutive years, with -$27.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, EBIT fell 49.2% year-over-year to -$27.3 million; the TTM figure through Mar 2026 stood at -$93.0 million (down 46.87% YoY), while the FY2025 annual figure was -$84.0 million, down 44.85% from the prior year.
• EBIT eased to -$27.3 million in Q1 2026 per TECX's latest filing, from -$21.5 million in the prior quarter.
• Across five years, EBIT topped out at -$9.4 million in Q4 2023 and bottomed at -$29.4 million in Q1 2022.
• Historically, EBIT has averaged -$19.4 million across 5 years, with a median of -$21.5 million in 2025.
• Annual changes were most pronounced in 2023 — EBIT soared 62.89% — and 2025, when it plunged 95.53%.
• Tectonic Therapeutic's EBIT stood at -$25.3 million in 2022, then jumped by 62.89% to -$9.4 million in 2023, then plunged by 49.25% to -$14.0 million in 2024, then tumbled by 53.78% to -$21.5 million in 2025, then decreased by 26.89% to -$27.3 million in 2026.
• Business Quant data shows TECX's EBIT at -$27.3 million in Q1 2026, -$21.5 million in Q4 2025, and -$21.9 million in Q3 2025.